WaveMan
WaveMan · Company
MEHA · Functional Brands Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

MEHA Functional Brands (MEHA) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Medicinal chemicals & botanical products · CIK 0001837254
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
1
13F, latest reported quarter

Functional Brands insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for Functional Brands Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing

no insider purchases or sales on record

0 transactions on record
See all insider buying · insider selling
Showing the latest few. to use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
1 fund bought in last quarter
Revenue
+0.7% year over year
below 52% of Pharma & Biotech
Margin
11.5% net margin
more than 82% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
0.5% of the float short (float per yahoo 2026-10-26) · 1.0 days to cover · settled 2026-09-30
below 79% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch MEHA

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

Who owns MEHA: institutional holders (13F)

13F holdings, latest reported quarter
Guardian Partners Inc.
38,972 sh
$203

Congress trades in MEHA

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

MEHA planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

MEHA mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Fidelity Extended Market Index Fund
$14.5K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 1 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

MEHA financials

Revenue growth
+0.7%
XBRL, annual
Net margin
11.5%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$6.7M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-126.9%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
n/a
capex not filed for the four quarters
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
Cash flow to debt
-9.75x
TTM operating cash flow over long-term 2026-06-30 plus current 2025-12-31 (6 months older than the period end)
Return on equity
n/a
average equity is zero or negative
Return on assets
-131.9%
TTM net income over ending balance 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-398.2%
operating income (EBIT proxy) over ending balance 2026-06-30 minus current liabilities
P/E, trailing
n/a
no close on file at or before the as-of date
Enterprise value
n/a
no close on file at or before the as-of date
FCF yield
n/a
no close on file at or before the as-of date
PEG, trailing
n/a
no close on file at or before the as-of date
Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-12
Revenue$6.6M$6.6M
Gross profit$3.5M$3.6M
Operating income-$1.4M-$229.1K
Net income$758.5K-$559.4K
EPS (diluted)0.01-0.08
Operating cash flow-$1.3M$2.0K
Cash$2.7M$211.6K
Long-term debt$140.5K$100.0K
SEC XBRL, fiscal years, as known on 2026-10-28

MEHA Stock Sonar score 4/7 axes

Find similar shapesCompare

MEHA ranks highest on risk and compliance (86th percentile) and growth (48th), and lowest on profitability (11th), among Pharma & Biotech peers.

Profitability
11
Inputs
  • Return on equityaverage equity is zero or negative
  • Return on assets-131.9% · 18 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-398.2% · 4 pct, sector of 576
Financial health
23
Inputs
  • Debt to equityequity is zero or negative, the ratio has no meaning
  • Cash flow to debt-9.75x · 23 pct, sector of 371
Growth
48
Inputs
  • Revenue growth, YoY+0.7% · 48 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Risk and compliance
86
Inputs
  • Short interest, % of float+0.5% · 86 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
3 not measured: Insider conviction, Institutional and government, US patents
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • Institutional and government needs 1 of 4 inputs, 0 present: fewer than five funds report holding it; no Congress trades in 365 days; no federal contracts in 180 days; no lobbying filings in the last four quarters
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies